5
Nov, 2020
RESCEU: Fighting Respiratory Syncytial Virus and its economic impact
Europe’s project RESCEU sheds new light on the fight against the Respiratory Syncytial Virus (RSV) and its economic impact
News
22
Apr, 2020
RECOVER enrolls first patients in its COVID-19 studies!
22 April 2020
RECOVER’s achievements on April 2020
14
Mar, 2020
RECOVER: a new project approved by EU to tackle COVID-19
Antwerp, Belgium – 11 March, 2020
Penta is partner in the new RECOVER project, which has been selected for funding by the European Union (2020 – 2022) to respond to the SARS-CoV-2 epidemic.
3
Mar, 2020
PREPARE activated to Mode 3 as COVID-19 cases in Europe increases
Antwerp, Belgium – 3 March 2020
PREPARE has decided to upgrade its response efforts to the novel Coronavirus (SARS-CoV-2) epidemic to Outbreak Research Response Mode 3
25
Feb, 2020
PREPARE continues active measures as novel Coronavirus outbreak in Italy unfolds
Antwerp, Belgium – 24 February 2020
With ongoing clusters in Iran, South Korea, Singapore, Thailand, Vietnam, Hong Kong, Japan and more recently in Italy, we anticipate further large clusters and possibly community-wide transmission in Europe and therefore are preparing
6
Feb, 2020
PREPARE activated to Mode 2 in response to novel Coronavirus cases in Europe
Antwerp, Belgium – 6 February 2020
“This is the first time that there is a harmonized European collaboration for data collection of patient data during an outbreak. It is a crucial step to enable sharing and comparing information to inform public health responses,’ explains Prof Herman Goossens, coordinator of PREPARE.
1
Apr, 2019
University of Antwerp, bioMérieux, and Wellcome Trust to coordinate VALUE-Dx, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics
Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019 The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitrodiagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. The purpose of VALUE-Dx is to transform medical practice to achieve more personalised, evidence-based antibiotic prescription and use in community care settings through the widespread use of clinical and cost-effective innovative diagnostic strategies. VALUE-Dx is co-funded […]
